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Background
Georgia has one of the nation’s largest populations of individuals with sickle cell disease (SCD) and thalassemia. For 
many of these individuals, blood transfusion may be needed on a regular, intermittent, or emergency basis. In order to 
avoid serious complications, like alloimmunization and iron overload, among patients who receive multiple transfusions in 
their lifetime, patients, physicians, and blood bank personnel need to know and follow specific, recommended practices.
The Centers for Disease Control and Prevention funds Georgia’s REdHHoTT project to reduce complications of 
therapeutic blood transfusion in SCD and thalassemia. As part of this work, the Georgia Health Policy Center surveyed 
Georgia hospital transfusion services (blood banks) to gauge adherence to currently recommended practices and to 
inform improvement strategies. 
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* Full results were published in Fasano, R. M., Branscomb, J., Lane, P., Josephson, 
C., Snyder, A., & Eckman, J. (2019). Transfusion service knowledge and 
immunohaematological practices related to sickle cell disease and thalassemia. 
Transfusion Medicine Reviews, https://doi.org/10.1111/tme.12580
Hospital Blood Bank Survey Results
Thirty-five institutions responded (71%), of which 
32 reported experience transfusing SCD patients 
and 11 reported experience transfusing thalassemia 
patients. Responding institutions that are classified as 
comprehensive sickle cell treatment centers (n = 3) or 
thalassemia treatment centers (n = 1) follow applicable 
practice recommendations. Results varied among the 
remaining hospitals, as illustrated below.
Contact the Georgia Health Policy Center to request 
grand rounds or consultation with specialists in 
thalassemia and SCD management, transfusion 
medicine, and blood bank practices.
Email: BloodDisorders@gsu.edu
Watch a continuing education course, Reducing 
Complications of Therapeautic Blood Transfusion in 
Sickle Cell Disease at ghpc.gsu.edu/cme
Learn more about REdHHoTT visit bit.ly/GHPC_SCDC
1 SCD recommendations:
Yawn, B. P., & John-Sowah, J. (2015). Management of sickle cell disease: recommendations from the 2014 expert panel report. American Family Physician, 92(12), 1069-
1076.
Davis, B. A., Allard, S., Qureshi, A., Porter, J. B., Pancham, S., Win, N., ... & British Committee for Standards in Haematology. (2017). Guidelines on red cell transfusion in    
sickle cell disease. Part I: principles and laboratory aspects. British Journal of Haematology, 176(2), 179.
Davis, B. A., Allard, S., Qureshi, A., Porter, J. B., Pancham, S., Win, N., ... & Ryan, K. (2017). Guidelines on red cell transfusion in sickle cell disease Part II: indications for
transfusion. British Journal of Haematology, 176(2), 192-209.
2 Thalassemia guidelines:
Taher, A., Vichinsky, E., Musallam, K., Cappellini, M. D., & Viprakasit, V. (2013). Guidelines for the management of non transfusion 
dependent thalassaemia (NTDT) Thalassaemia International Federation, Nicosia, Cyprus.
This publication is supported by Cooperative Agreement DD14-1406, funded by the Centers for Disease Control and Prevention 
(CDC). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the CDC or the U.S. 
Department of Health and Human Services.
Commonly Cited Challenges
Respondents were given an open-ended question to describe challenges they face regarding transfusing patients with 
hemoglobin disorders. The following challenges were cited multiple times:
• Lack of standard policies/procedures (within a health system or across hospitals) for red blood cell phenotyping 
and blood product matching
• Securing appropriately matched red blood cell units for alloimmunized patients
• Lack of standardized procedures for notifying transfusion services that a patient has either SCD or thalassemia
• Obtaining a reliable and complete transfusion and antibody history across multiple hospital systems
What Providers Can Do
• Review the full report on this study and the practice recommendations
• View a web-based video series for clinicians on transfusion recommendations for SCD, with free continuing medical 
education and continuing nursing education credits provided through CDC: ghpc.gsu.edu/cme
• View a recorded webinar series for sickle cell patients and caregivers on avoiding transfusion complications, as part 
of the Sickle Cell Community Consortium’s Warrior University: sicklecellconsortium.org/warrior-u-transfusions
• Contact the Georgia Health Policy Center to request grand rounds or consultation with specialists in thalassemia 
and SCD management, transfusion medicine, and blood bank practices as part of the REdHHoTT project. Email 
BloodDisorders@gsu.edu
Adherence to selected thalassemia transfusion recommendations2 among nonthalassemia treatment centers
Perform extended red blood cell antigen typing that includes at least C, c, D, E, e, and Kell and transfuse 
with units prophylactically matched for ABO and Rh (C, c, D, E, e) and Kell.
20%
Before each transfusion, run a full cross-match and screen for new antibodies, or in centers that meet 
regulatory requirements, an electronic cross-match.
50%
Adherence to selected SCD transfusion recommendations1 among noncomprehensive treatment centers
Perform extended red blood cell phenotyping and prophylactically match units, including for ABO/Rh(D) 
and at least C, c, D, E, e, and Kell, to reduce likelihood of patient developing antibodies
71%
Provide sickle cell trait–negative red blood cells. 100%
Obtain patient transfusion history including locations of prior transfusions; ask blood bank to contact 
hospitals where patient reported receiving previous transfusions to obtain transfusion information.
• Use a reliable method to identify SCD patients prior to transfusion, such as a required question-
answer field on type, screen, or crossmatch orders
• Have a routine system in place to identify SCD patients who may have received transfusions 
elsewhere
33%
77%
